Takeda Pharmaceutical is launching a comprehensive “Transformation Program” for fiscal year 2026 as it prepares for a leadership transition and a pivotal shift toward new growth drivers. The move aims to offset revenue losses triggered by generic competition for its former blockbuster drugs.
Efficiency Drive and Workforce Reductions The 2026 transformation initiative focuses on centralizing corporate functions and reducing management layers. Takeda expects to cut approximately 4,500 roles globally, incurring a one-time restructuring cost of 170 billion yen ($1.07 billion). However, the drive is projected to deliver over 200 billion yen ($1.26 billion) in annualized savings by 2028.
Strategic “Two-Horizon” Growth Path Under the incoming CEO Julie Kim, Takeda is adopting a two-phase growth strategy:
-
Horizon One: Focusing on the launch of three high-potential assets: oveporexton (narcolepsy), rusfertide (polycythemia vera), and zasocitinib (psoriasis). Both oveporexton and rusfertide are under priority FDA review and could hit the U.S. market in late 2026.
-
Horizon Two: Maximizing early-launch revenues while preparing the next wave of late-stage pipeline candidates for commercialization.
Navigating the Post-Generic Landscape The steep sales decline of the ADHD medication Vyvanse due to patent expiration has been a significant headwind. Nevertheless, with growth products like Entyvio and Takhzyro now accounting for 51% of total revenue, Takeda anticipates that 2026 will be the “pivot year,” marking the end of major generic impacts and the start of a new era of profitable expansion.